Pàgina inicial > Resultats de la cerca: Cui, X.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
20 p, 620.3 KB Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors / Moreno, V. (Hospital Universitario Fundación Jiménez Díaz) ; Greil, R. (IIIrd Medical Department. Paracelsus Medical University. Salzburg Cancer Research Institute) ; Yachnin, J. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ; Wermke, M. (Medical Clinic I. University Hospital Carl Gustav Carus. NCT/UCC Early Clinical Trial Unit) ; Arkenau, Hendrik-Tobias (Cancer Institute. University College London) ; Basque, J.R. (Novartis Pharma AG) ; Nidamarthy, P.K. (Novartis Healthcare Private Limited) ; Kapoor, S. (Novartis Healthcare Private Limited) ; Cui, X. (Novartis Institutes for BioMedical Research) ; Giovannini, M. (Novartis Pharmaceuticals Corporation)
Purpose: In the Phase II GEOMETRY mono-1 study, the potent and selective mesenchymal-epithelial transition (MET) inhibitor capmatinib exhibited considerable efficacy in MET exon 14 skipping (METex14)-mutated metastatic non-small cell lung cancer at a dose of 400 mg BID. [...]
2021 - 10.1016/j.clinthera.2021.04.006
Clinical Therapeutics, Vol. 43 Núm. 6 (june 2021) , p. 1092-1111  
Registre complet - Creative Commons
2.
0 p, 567.1 KB Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer : clinical and biomarker results from a phase I trial / Schuler, M. (German Cancer Consortium (DKTK), Partner Site University Hospital Essen, Essen, Germany) ; Berardi, R. (Università Politecnica delle Marche-Ospedali Riuniti) ; Lim, W.-T (National Cancer Centre Singapore) ; de Jonge, M. (Erasmus MC Cancer Center, Rotterdam) ; Bauer, Todd M (Sarah Cannon Research Institute, and Tennessee Oncology) ; Azaro, Analía (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia) ; Gottfried, M. (Oncology Institute of Meir Medical Center) ; Han, J.Y (Center for Lung Cancer, National Cancer Center (Corea del Sud)) ; Lee, D. H. (University of Ulsan College of Medicine (República de Corea)) ; Wollner, M. (Rambam Health Care Campusm (Israel)) ; Hong, David (MD Anderson Cancer Center (Estats Units d'Amèrica)) ; Vogel, A. (Hannover Medical School (Alemanya)) ; Delmonte, A. (Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori) ; Akimov, Mikhail (Novartis Pharma (Siïssa)) ; Ghebremariam, S. (Oncology Global Development-BDM) ; Cui, X. (Novartis Institutes for Biomedical Research) ; Nwana, N. (Oncology Precision Medicine) ; Giovannini, M. (Novartis Pharmaceuticals Corporation(Estats Units d'Amèrica)) ; Kim, T. M. (Seoul National University Hospital)
Dysregulation of receptor tyrosine kinase MET by various mechanisms occurs in 3%-4% of non-small-cell lung cancer (NSCLC) and is associated with unfavorable prognosis. While MET is a validated drug target in lung cancer, the best biomarker strategy for the enrichment of a susceptible patient population still remains to be defined. [...]
2020 - 10.1016/j.annonc.2020.03.293
Annals of oncology, Vol. 31 (march 2020) , p. 789-797  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem